Morning Overview on MSN
A new two-pill combo just slashed LDL cholesterol by 48.6% in a phase 3 trial — the sharpest drop ever logged without adding a statin to the mix
For the roughly 30 million American adults who have been told their cholesterol is too high but cannot stomach a statin, the ...
WHITEHOUSE STATION, New Jersey — Merck has resubmitted a new drug application (NDA) for the combination atorvastatin and ezetimibe (Zetia) tablet to the US Food and Drug Administration (FDA). Back in ...
A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...
Please provide your email address to receive an email when new articles are posted on . Obicetrapib plus ezetimibe lowered LDL nearly 50% vs. placebo in patients with high atherosclerotic risk.
Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Treatment with combination ezetimibe and simvastatin plus extended-release niacin may aid patients ...
MAASTRICHT, the Netherlands—Use of a fixed-dose combination of bempedoic acid and ezetimibe in statin-treated patients at high risk for cardiovascular disease significantly lowers LDL cholesterol ...
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GMbH (hereafter, ‘Daiichi Sankyo’) today announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination ...
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events ...
The FDA has approved a new combination drug from Merck for lowering cholesterol. The drug, which will carry the brand name of Liptruzet, is a combination of two previously approved ...
Moderate-intensity statin with ezetimibe combination therapy was confirmed to be effective on low-density lipoprotein cholesterol (LDL-C) reduction in patients at very high risk of atherosclerotic ...
A combination tablet containing the cholesterol-lowering drugs ezetimibe and atorvastatin is back on the path to possible FDA approval, according to Merck, which already markets Zetia (ezetimibe) and ...
Dallas, Texas— The US Food and Drug Administration (FDA) has approved a new lipid-lowering combination tablet that includes atorvastatin, which went off patent in 2011, and ezetimibe (Zetia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results